Emodepside targets SLO-1 channels of Onchocerca ochengi and induces broad anthelmintic effects in a bovine model of onchocerciasis

PLoS Pathog. 2021 Jun 2;17(6):e1009601. doi: 10.1371/journal.ppat.1009601. eCollection 2021 Jun.

Abstract

Onchocerciasis (river blindness), caused by the filarial worm Onchocerca volvulus, is a neglected tropical disease mostly affecting sub-Saharan Africa and is responsible for >1.3 million years lived with disability. Current control relies almost entirely on ivermectin, which suppresses symptoms caused by the first-stage larvae (microfilariae) but does not kill the long-lived adults. Here, we evaluated emodepside, a semi-synthetic cyclooctadepsipeptide registered for deworming applications in companion animals, for activity against adult filariae (i.e., as a macrofilaricide). We demonstrate the equivalence of emodepside activity on SLO-1 potassium channels in Onchocerca volvulus and Onchocerca ochengi, its sister species from cattle. Evaluation of emodepside in cattle as single or 7-day treatments at two doses (0.15 and 0.75 mg/kg) revealed rapid activity against microfilariae, prolonged suppression of female worm fecundity, and macrofilaricidal effects by 18 months post treatment. The drug was well tolerated, causing only transiently increased blood glucose. Female adult worms were mostly paralyzed; however, some retained metabolic activity even in the multiple high-dose group. These data support ongoing clinical development of emodepside to treat river blindness.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cattle
  • Cattle Diseases / drug therapy*
  • Depsipeptides / therapeutic use*
  • Filaricides / therapeutic use*
  • Large-Conductance Calcium-Activated Potassium Channels / drug effects*
  • Onchocerca / drug effects
  • Onchocerciasis / drug therapy*
  • Onchocerciasis / veterinary*

Substances

  • Depsipeptides
  • Filaricides
  • Large-Conductance Calcium-Activated Potassium Channels
  • emodepside

Associated data

  • Dryad/10.5061/dryad.vhhmgqns0

Grants and funding

This study was funded by Bayer AG (https://www.bayer.com/en) through contract research awarded to BLM (University of Liverpool) and to AS and LR (INVENesis). SS, HF, SRH, GMS, RK, CT, MGS, and DK are employees of Bayer, or were employees of Bayer when the work was undertaken. With the exception of the listed authors, Bayer AG had no role in the design or conduct of the experiments, analysis, or interpretation of the data.